tezacaftor ivacaftor
Selected indexed studies
- Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. (Lancet Respir Med, 2025) [PMID:39756424]
- Tezacaftor/ivacaftor for cystic fibrosis. (Aust Prescr, 2019) [PMID:31631935]
- Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review. (Children (Basel), 2023) [PMID:36980112]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials. (2025) pubmed
- Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review. (2023) pubmed
- Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation. (2025) pubmed
- PMID:39965067 (2024) pubmed
- Tezacaftor/ivacaftor for cystic fibrosis. (2019) pubmed
- Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis. (2021) pubmed
- Elexacaftor/tezacaftor/ivacaftor outpatient desensitization. (2022) pubmed
- Neuropsychiatric symptoms with elexacaftor/tezacaftor/ivacaftor: What does this mean for children? (2024) pubmed
- Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy. (2020) pubmed
- The clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) for people with CF without a F508del variant: A systematic review and meta-analysis. (2024) pubmed